NCT06049342View on ClinicalTrials.gov

A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

May 31, 2025

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

NCR100 injection

Subjects will receive a one-dose intra-articular NCR100 injection.

Sponsors
All Listed Sponsors
collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

Beijing Luhe Hospital

OTHER

lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY